Literature DB >> 11346642

Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation.

P Sachdev1, Y X Jiang, W Li, T Miki, H Maruta, M S Nur-E-Kamal, L H Wang.   

Abstract

Insulin-like growth factor I receptor (IGFR) plays an important role in cell growth and transformation. We dissected the downstream signaling pathways of an oncogenic variant of IGFR, Gag-IGFR, called NM1. Loss of function mutants of NM1, Phe-1136 and dS2, that retain kinase activity but are attenuated in their transforming ability were used to identify signaling pathways that are important for transformation of NIH 3T3 cells. MAPK, phospholipase C gamma, and Stat3 were activated to the same extent by NM1 and its two mutants, suggesting that activation of these pathways, individually or in combination, was not sufficient for NM1-induced cell transformation. The mutant dS2 has decreased IRS-1 phosphorylation levels and IRS-1-associated phosphatidylinositol 3'-kinase activity, suggesting that this impairment may be in part responsible for the defectiveness of dS2. We show that Rho family members, RhoA, Rac1, and Cdc42 are activated by NM1, and this activation, particularly RhoA and Cdc42, is attenuated in both mutants of NM1. Dominant negative mutants of Rho, Rac, and Cdc42 inhibited NM1-induced cell transformation, as measured by focus and colony forming ability. Dominant negative Rho most potently inhibited the focus forming activity, whereas Cdc42 was most effective in inhibiting the colony forming ability of NM1-expressing cells. Conversely, constitutively activated (ca) Rho is more effective than ca Rac or ca Cdc42 in rescuing the focus forming ability of the mutants. By contrast, ca Cdc42 is most effective in rescuing the colony forming ability of both mutants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11346642     DOI: 10.1074/jbc.M010995200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

Review 1.  Cell growth and metastasis in pancreatic cancer: is Vav the Rho'd to activation?

Authors:  Daniel D Billadeau
Journal:  Int J Gastrointest Cancer       Date:  2002

2.  ROCK and nuclear factor-kappaB-dependent activation of cyclooxygenase-2 by Rho GTPases: effects on tumor growth and therapeutic consequences.

Authors:  Salvador Aznar Benitah; Pilar F Valerón; Juan Carlos Lacal
Journal:  Mol Biol Cell       Date:  2003-07       Impact factor: 4.138

3.  Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.

Authors:  Peter W Schlosshauer; Wei Li; Kai-Ti Lin; Joseph L-K Chan; Lu-Hai Wang
Journal:  Gynecol Oncol       Date:  2009-07-02       Impact factor: 5.482

Review 4.  Inflammatory breast cancer: relationship between growth factor signaling and motility in aggressive cancers.

Authors:  Kenneth L van Golen
Journal:  Breast Cancer Res       Date:  2003-04-04       Impact factor: 6.466

Review 5.  Rho GTPases modulate malignant transformation of tumor cells.

Authors:  Jose L Orgaz; Cecilia Herraiz; Victoria Sanz-Moreno
Journal:  Small GTPases       Date:  2014-05-08

6.  Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway.

Authors:  Yan Li; Yi Jiang; Yicong Wan; Lin Zhang; Weiwei Tang; Jingjing Ma; Shan Wu; Wenjun Cheng
Journal:  J Biomed Res       Date:  2012-12-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.